Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. MRNA led at +60.23% ($130.38 → $208.90), closing 74.55% of its range with an 84.64% realized vol against 73.78% implied — a 3.49x surprise. TEM (+54.35%) posted the period's biggest vol surprise at 3.79x, and QURE registered 183.87% realized against 81.10% implied (2.68x) while falling 52.16%. KPTI was the worst performer at -55.96%, closing at just 2.17% of its range.

Options markets underpriced the move in most of the large and mid-caps: AMGN and SYK both realized 2.18x implied, MRK 1.88x, ABBV and HIMS 1.72x. The opposite held in the highest-IV names — CDXS (420.31% implied, 0.35x), DBVT (208.59%, 0.37x), XLV (0.52x) and HUM (0.69%x implied 86.32%) all realized far less than priced, a classic pattern where headline IV on low-priced or index products overstates delivered movement.

Range placement skewed bearish: ADMA closed highest at 81.34%, while MGNX (1.42%), STIM (1.90%), ABT (1.50%), JNJ (2.43%) and KPTI finished on their lows.

Broader Market Context

Differential behavior within the sector. The spread between the top and bottom of this list exceeds 115 percentage points, which is far wider than the sector ETF itself: XLV moved just +4.09% with 12.82% realized vol — the lowest in the group by a wide margin. That gap is telling. When the index barely budges while constituents swing 50%+ in both directions, the sector is not being traded as a single macro block; it is being traded name by name. The clearest fault line runs between biotech/innovation names (MRNA +60%, TEM +54%, EBS +28%, ADMA +20%, HIMS +19%) and managed care/payors (CNC -14.6%, CVS -14.0%, HUM -12.1%, ELV -12.0%, UNH -10.8%), with every major insurer finishing near its lows. Large-cap pharma sat in between, modestly positive (ABBV +9.2%, LLY +9.1%, MRK +7.9%, GILD +7.9%), while devices diverged (SYK +8.8% vs. ABT -9.7%).

Rotation vs. idiosyncratic moves. This looks like both at once:

• The uniform, same-direction weakness across all five managed-care names — all closing between 5.75% and 20.51% of range — is consistent with a group-level de-rating rather than company-specific accidents.
• The biotech strength, by contrast, looks idiosyncratic: MRNA and TEM's 3.49x and 3.79x vol surprises are more characteristic of discrete catalysts than of flows.
• Micro-caps (KPTI, STIM, DBVT, MGNX, CDXS, QURE) all fell hard and closed near lows, which is more consistent with risk-off positioning in speculative, cash-burning equities than with a defensive rotation *into* healthcare.

Plausible current drivers. The payor drawdown is consistent with ongoing pressure around medical cost trends, utilization, and reimbursement or policy uncertainty — the kind of factors that tend to hit insurers as a bloc. Strength in vaccine, diagnostics and digital-health names likely reflects renewed risk appetite for clinical and commercial catalysts, possibly amplified by M&A speculation. Meanwhile, the collapse in small-cap biotech alongside elevated implied vol (CDXS at 420%, KPTI at 341%) is consistent with a financing-sensitive cohort reacting to rate and liquidity conditions. Treat these as plausible framings, not confirmed events.